Maintenance therapy week | 0 | 4 | 8 | 12 | 24–36-48-etc | |
---|---|---|---|---|---|---|
Timeline for standard and experimental arm | Screening d − 14 to 0 | Start MT d1 | 2nd cycle MT d 29 | 3rd cycle MT d 57 | 4th cycle MT d 85 | Every 12 weeks till end of maintenance |
Informed consenta | X | |||||
Medical Historyb | X | X | X | X | X | |
Physical Examination | X | X | X | X | X | X |
Height, weight, BSAc | X | X | X | X | ||
Vital signsd | X | X | X | X | ||
Performance Statuse | X | X | X | X | ||
Pregnancy testf | X | (X) | (X) | (X) | (X, monthly) | |
Echocardiogram | Xq | X (end of MT) | ||||
Eligibility and registrationg | X | |||||
Concomitant Med | X | X | X | X | X | |
Treatment | ||||||
LP with ITh | X | ALLTogether1 | ||||
Maintenance therapy (6MP/MTX/6TG/VCR/DEXA) | Continuously | |||||
Safety FU | ||||||
CBC and differential | X | X | X | X | X | X |
Chemistry panel Ai | X | X | X | X | X | |
Chemistry panel Bj | X | |||||
Amylase, Lipase | X | X | ||||
Serum Ig levelsk | X | X | X | |||
Immunophenotyping of B-cellsl | (X) | (X) | (X) | |||
Adverse events | X | X | X | X | X | ALLTogether1 |
AESIsm | X | X | X | X | X | X |
6MP/MTX metaboliteso | X | X | X | X (monthly) | ||
Efficacy FU | ||||||
Disease/survival statusp | X | X | ALLTogether1 |